Pricing Log in Create free account

Dermata Therapeutics, Inc. (DRMA) vs GRI Bio, Inc. (GRI)

Dermata Therapeutics, Inc. and GRI Bio, Inc. are both Biotechnology companies. Dermata Therapeutics, Inc. is the larger, with a market value of $3.8M against $3.4M — 1.1× the size. Across the 9 metrics below, GRI Bio, Inc. leads on 6 and Dermata Therapeutics, Inc. on 3.

Valuation

Metric DRMA GRI Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 0.89 0.32 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.07 0.77 0.66
EV/Sales n/m n/m 9.02
Earnings yield (585.53%) (2,802.73%) (32.88%)
Free cash flow yield (259.42%) (313.92%) (23.13%)

Profitability

Metric DRMA GRI Biotechnology median
Gross margin — 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (183.89%) (142.02%) (51.96%)
Return on assets (139.93%) (113.27%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DRMA GRI Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 89.84% 92.12% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DRMA GRI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.81 10.30 4.97
Net debt to EBITDA 0.97 0.69 1.01

Dividend

Metric DRMA GRI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DRMA GRI Biotechnology median
Market cap 3.78m 3.39m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack